| Popis: |
Somatostatin receptor-targeting peptides are widely being used for imaging and therapy of neuroendocrine tumors. Peptide receptor radionuclide therapy (PRRT) with e.g. 177Lu labeled somatostatin analogues in neuroendocrine tumor patients has resulted in symptomatic improvement, prolonged survival and enhanced quality of life. Yet, much profit can be gained from improving the receptor-targeting strategies available and developing new strategies, e.g. targeting other tumor-specific receptors, such as gastrin-releasing peptide (GRP) receptors and gastrin/cholecystokinin (CCK) receptors, and combining PRRT with other treatment strategies like chemotherapy or co-treatment with radiosensitizers. |
